1
|
Vojjala N, Peshin S, Kattamuri LPV, Iqbal R, Dharia A, Jayakumar J, Iftekhar R, Singh S, Balla M, Villa Celi CS, Ramachandran R, Prabhu R, Yadav SK, Krishnamoorthy G, Singh V, Seegobin K. Direct-Acting Oral Anticoagulants in the Management of Cerebral Venous Sinus Thrombosis-Where Do We Stand? Biomedicines 2025; 13:189. [PMID: 39857772 PMCID: PMC11759824 DOI: 10.3390/biomedicines13010189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2024] [Revised: 12/16/2024] [Accepted: 12/26/2024] [Indexed: 01/27/2025] Open
Abstract
BACKGROUND Cerebral venous sinus thrombosis (CVT) is a rare cause of stroke, constituting 0.5-3% of all strokes with an extremely varied spectrum of presentation, predisposing factors, neuroimaging findings, and eventual outcomes. A high index of suspicion is needed because timely diagnosis can significantly alter the natural course of the disease, reduce acute complications, and improve long-term outcomes. Due to its myriad causative factors, protean presentation, and association with several systemic diseases, CVT is encountered not only by neurologists but also by emergency care practitioners, internists, hematologists, obstetricians, and pediatricians. DISCUSSION Anticoagulation remains the mainstay of treatment for CVT. Heparin and warfarin previously had been the anticoagulation of choice. Recently there has been an increased interest in utilizing direct-acting oral anticoagulants in the treatment of CVT given comparable safety and efficacy with ease of utilization. However recent clinical guidelines given by multiple societies including the American Stroke guidelines and European guidelines do not include these agents so far in their treatment recommendations. Ongoing multicentric clinical trials are currently reviewing the role of these agents in both short-term as well as long-term. Our review of the literature supports the safety and reinforces the efficacy of DOAC in the treatment of CVT. Additionally, patient satisfaction has been shown to be better with the use of DOAC. In conclusion, DOAC continues to have a valid role in the management of CVT.
Collapse
Affiliation(s)
- Nikhil Vojjala
- Department of Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI 48341, USA; (N.V.); (R.P.); (G.K.)
| | - Supriya Peshin
- Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA;
| | | | - Rabia Iqbal
- Internal Medicine, Brooklyn Hospital Center, Brooklyn, NY 11201, USA; (R.I.); (J.J.)
| | - Adit Dharia
- HCA Florida Oak Hill Hospital, Brooksville, FL 34613, USA;
| | - Jayalekshmi Jayakumar
- Internal Medicine, Brooklyn Hospital Center, Brooklyn, NY 11201, USA; (R.I.); (J.J.)
| | - Rafi Iftekhar
- Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA;
| | - Shagun Singh
- Department of Internal Medicine, Banner Health, University of Arizona, Tucson, AZ 85719, USA; (S.S.); (R.R.)
| | - Mamtha Balla
- MD Anderson Cancer Center, Department of Infectious Disease Transplant, University of Texas, Houston, TX 77030, USA;
| | | | - Ramya Ramachandran
- Department of Internal Medicine, Banner Health, University of Arizona, Tucson, AZ 85719, USA; (S.S.); (R.R.)
| | - Rishab Prabhu
- Department of Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI 48341, USA; (N.V.); (R.P.); (G.K.)
| | - Sumeet K. Yadav
- Department of Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN 56001, USA;
| | - Geetha Krishnamoorthy
- Department of Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI 48341, USA; (N.V.); (R.P.); (G.K.)
| | - Vijendra Singh
- Department of Hematology-Oncology, Karmanos Cancer Center, Wayne State University School of Medicine, Detroit, MI 48201, USA;
| | - Karan Seegobin
- Department of Medical Oncology, Mayo Clinic Health System, Mankato, MN 56001, USA;
| |
Collapse
|
2
|
Luo Y, Tian X, Wang X. Diagnosis and Treatment of Cerebral Venous Thrombosis: A Review. Front Aging Neurosci 2018; 10:2. [PMID: 29441008 PMCID: PMC5797620 DOI: 10.3389/fnagi.2018.00002] [Citation(s) in RCA: 82] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Accepted: 01/08/2018] [Indexed: 12/13/2022] Open
Abstract
Cerebral venous thrombosis (CVT), also called cerebral venous sinus thrombosis (CVST), is a cerebrovascular disease with diverse clinical manifestations that often affects young adults, women of childbearing age, and children. It's most common clinical manifestations are headache, seizures, altered consciousness, and neurological focal signs on physical examination. CVT can manifest as a single symptom, or it can present as a syndrome consisting of multiple symptoms. This non-specific clinical picture makes diagnosing CVT difficult. Although the mortality rate of CVT has been significantly reduced by improvements in treatment and diagnostic techniques, the mortality rate of severe CVT remains as high as 34.2%. Survivors of this type of CVT have varying degrees of residual symptoms and are not able to return to their previous work. Hence, we performed a comprehensive literature search in the PubMed, EMBASE, and Medline databases to review the diagnosis and treatment of CVT.
Collapse
Affiliation(s)
- Yaxi Luo
- Chongqing Key Laboratory of Neurology, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Xin Tian
- Chongqing Key Laboratory of Neurology, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Xuefeng Wang
- Chongqing Key Laboratory of Neurology, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.,Center of Epilepsy, Beijing Institute for Brain Disorders, Beijing, China
| |
Collapse
|